Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary C

Indication
Bladder Cancer; Urothelial Carcinoma Bladder; Urothelial Carcinoma

Other upcoming events for URGN

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel For
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel For
Patent ExpiryPatent/Exclusivity Expiry: ZUSDURI
Patent ExpiryPatent/Exclusivity Expiry: JELMYTO

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary C — URGN Phase 3 Readout | BioSniper